AYTU - CIK 0001385818
The table below shows AYTU BIOPHARMA, INC's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$618.00K | -$1.19M | -$211.00K | -$9.15M | -$3.79M | $19.70M |
| Capital expenditure | $0.00 | $136.00K | - | - | - | - |
| Investing cash flow | $0.00 | $381.00K | -$76.00K | $42.00K | -$86.00K | - |
| Dividends paid | - | - | - | - | - |
AYTU BIOPHARMA, INC reported operating cash flow of -$1.94M for fiscal year 2025. That is down 39.6% from -$1.39M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$37.70K (FY 2013) to -$1.94M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $2.30M | $911.00K | -$2.73M | $13.56M | -$5.46M | - |